The araC gene encodes a positive regulatory protein required for L-arabinose utilization in Escherichia coli. Transcription from the araC promoter has been shown to be under positive control by cAMP receptor protein and under negative control by its protein product (autoregulation). This work describes the identification of the region of the araC promoter that interacts with the cAMP receptor protein to mediate catabolite repression. A 3-base-pair deletion centered 60 base pairs from the transcriptional initiation site results in a mutant araC promoter that, in the absence of araC protein, reduces transcriptional activity when compared with the wildtype promoter and is unresponsive to various concentrations of intracellular cAMP in vivo. The same deletion results in a lowered affinity of the araC promoter for cAMP receptor protein in vitro. However, this lowered affinity for the mutant araC promoter does not result in substantial reduction of intracellular araC protein because autoregulation of the araC gene dominates catabolite repression. The 3-base-pair deletion in the cAMP receptor protein binding site of the araC promoter does not affect catabolite repression of the adjacent araBAD operon. The implications of these results on current models for expression of the araBAD operon and the araC gene are discussed.
The regulatory region for the araC gene is adjacent to the regulatory region for the araBAD operon. Their respective promoters are transcribed in opposite directions (5) and their transcriptional initiation sites are separated by 147 base pairs (bp) (6) . The nucleotide sequence of this region of DNA has been determined (7, 8) and it will be referred to as the ara regulatory region. Binding sites for regulatory proteins have been identified between the two transcriptional initiation sites (refs. 4 and 9; see Fig. 1 ). The localization of the regulatory protein binding sites in the promoter region has been the basis for several proposed models of the regulation of the araBAD operon and the araC gene (4, 9, 10) . The portions of these models that are relevant to this work are the following. The DNase I protection studies form the basis for the most recent models for araBAD and araC expression (4, 9) . Although consistent with physiological data, these models have not been tested with promoter mutations as controls. We have described the construction of plasmids containing 3-bp deletions in either the araC activator binding site (AACT) or the cAMP-CRP binding site (ACRP) (12) . These deletions were moved from plasmids onto the bacterial chromosome. The 3-bp deletion in the cAMP-CRP binding site did not reduce expression or affect catabolite repression of the araBAD operon and hence experiments were focused on the regulation of the araC gene. The in vivo effect of the ACRP mutation was determined with araC-lacZ transcriptional gene fusions. In vitro data on the effect of the ACRP mutation were obtained from transcription run-off experiments and DNase I protection studies (13) . We conclude that positive regulation of the araC gene by the cAMP-CRP complex occurs when the complex binds to a region of DNA 38 to 71 bp upstream from its transcriptional initiation site. In the absence of this cAMP-CRP binding site, the amount of functional araC protein in the cell remains close to wild-type levels because autoregulation of the araC gene by its own protein product dominates cAMP-CRP-mediated regulation. Our data are not consistent with the proposal that the ara-BAD operon and the araC gene share a common site for cAMP-CRP-mediated regulation (4) or that the site deleted by ACRP is involved only in araBAD regulation (9) .
MATERIALS AND METHODS
Transformations (14) , ,B-galactosidase (EC 3.2.1.23) assays (15), L-arabinose isomerase (EC 5.3.1.4) assays (16) , and ribulokinase (EC 2.7.1.16) assays (16) were done as described. Restriction fragments were labeled at their 3' ends with [a-32P]dATP, the appropriate unlabeled dNTPs, and DNA polymerase large fragment (17) . After digestion with a second restriction enzyme, single end-labeled restriction fragments were purified on polyacrylamide gels (18) . DNase I protection studies and in vitro run-off transcription studies were done as described (4) . CRP protein was purified (19) from strain pp47 containing plasmid pHA7 (20) . RNA poly- Genetic nomenclature is as described by Bachmann and Low (25) and Novick et al. (26) . For the purposes of this table, the AACT mutation is defined as A(araBi)2000 and the ACRP mutation is defined as A(araCp)2001 based on the above nomenclature proposals and results obtained in this study. All strains are derivatives of E. coli B/r strain UP1000. *Stabilization of the Mu prophage was as described (23) . merase (EC 2.7.7.6) was the gift of A. J. Carpousis. Preparations of araC protein were obtained from strain MC1061 (21) containing an over-producing araC plasmid utilizing the leftward promoter of phage X (unpublished data). The araC protein was purified (unpublished data) to approximately 80% purity as judged by analysis on NaDodSO4/polyacrylamide gels. Restriction endonucleases were from commercial sources. Bacterial strains and plasmids are listed in Table 1 . The construction of strains used originally in this work has been presented elsewhere (27) .
RESULTS
Regulation of araBAD in Strains Containing ara Regulatory Mutations on the Bacterial Chromosome. The effect of a promoter mutation on gene expression should be determined with the mutation on the chromosome. Two mutations created by oligonucleotide-directed mutagenesis, AACT and ACRP ( Fig. 1) , were transferred from plasmids pCGM1 and pCGM3 (12) (27) . In all cases a 2.3-kilobase-pair restriction fragment hybridized to the probe, a result that is consistent with the BstEII restriction sites surrounding the ara regulatory region.
(ii) The ara regulatory region from strain LA2000 or LA2001 was cloned into plasmid pAH15 by in vivo recombination (28) . Subsequent DNA sequence determinations showed that the correct mutation was present on the bacterial chromosome with no other nucleotide changes in the ara regulatory region.
The effect of the AACT and ACRP mutations on araBAD regulation was determined by measuring L-arabinose isomerase (araA gene product) and ribulokinase (araB gene product) activity in cell-free extracts. Strains UP1000 (ara+) and LA2001 (ACRP) exhibited catabolite repression in that growth in the presence of glucose decreased enzyme levels 70-80o when compared with cells grown in the presence of glycerol (Table 2 ). In the case of strain LA2000 (AACT), Larabinose isomerase specific activity averaged approximately 0.3 unit regardless of the carbon source and ribulokinase activity was not detected (data not shown).
Effect of the ACRP Mutation on the araC Promoter. The ACRP mutation deletes 3 bp of DNA in a region that binds the cAMP-CRP complex in vitro. This region of DNA has been proposed to regulate only araBAD (9) or to regulate both araBAD and araC (4) . The data in Table 2 suggested that ACRP does not affect regulation of the araBAD operon; hence, we determined the effect of the ACRP mutation on araC promoter activity.
The regulation of the araC gene was originally studied through the use of an araC-lacZ transcriptional gene fusion because the protein product was difficult to assay directly (3). Similar strains were constructed and assayed for a-galactosidase, the product of the lacZ gene, to quantitate tran-FIG. 1. Location of protein binding sites in the ara regulatory region. The top line shows the pertinent restriction sites used in this study with respect to the ara regulatory region. The BamHI site is at -44, Ava II is at -169, and BstEII is at -207. Transcriptional initiation sites for the araBAD operon and the araC gene are shown as wavy arrows pointed in the direction of transcription. The protein binding sites (4, 9) are shown above the DNA sequence (dark heavy line) that is numbered with respect to the araBAD transcriptional start site, which is taken as + 1. They are abbreviated as follows: RNAP, RNA polymerase binding site; ACT, araC activator binding site; CRP, the cAMP-CRP binding site; REP, the araC repressor binding site. Shown below is the nucleotide sequence of the araC activator binding site and the cAMP-CRP binding site. The AACT deletion and the ACRP deletion are denoted by inverted triangles while the synthetic oligonucleotide sequences used to create the deletions are underlined.
Genetics: Miyada et aL scription from the araC promoter. Strain LA920, which contains the wild-type araC promoter fused to the lacZ gene, was grown in the presence of glycerol, glucose, or glucose plus 2.5 mM cAMP. As shown in Table 3 , ,3galactosidase activity was greatest when glycerol was the available carbon source and least when glucose was the carbon source. The addition of cAMP to the medium reversed the repressive effect glucose had on the araC promoter. These results are consistent with the original study that showed that cAMP-CRP mediated regulation of the araC promoter (3). The ACRP mutation was placed cis to the identical araC-lacZ gene fusion by in vivo recombination with a plasmid carrying the ACRP mutation. In the resulting strain, f3galactosidase activity was lower than that obtained with the glucose-repressed wild-type promoter and the promoter activity was unresponsive to the different carbon sources present in the growth medium (Table 3) .
Autoregulation and the ACRP Mutation. Casadaban has shown that araC gene transcription is regulated by its own product (3). To determine whether the ACRP mutation reduced the amount of araC protein synthesized in vivo, the amount of araC produced from the chromosome was determined by measuring the P-galactosidase synthesized from a plasmid-encoded araC-lacZ translational gene fusion. Lowered p-galactosidase activity should be proportional to an increase in the intracellular concentration of araC protein.
Plasmid pLJS1 is a derivative of pSC101, a low-copy-number plasmid (30) . Plasmid pLJS1 contains a truncated araA (Table 4) . If one assumes a linear relationship between the concentration of araC protein in the cell and the amount of repression seen in this system, then the ACRP mutation reduces the amount of araC protein produced in the cell by 8%. These results suggest that absence of the cAMP-CRPmediated, positive gene regulation of the araC gene has little effect on the amount of araC protein produced by the cell in the absence of L-arabinose. Experiments with the araC-lacZ fusion on the chromosome and araC or ACRP araC on the high-copy-number plasmid pBR322 gave results that led to the same conclusion (27) .
In Vitro Transcription Experiments. The effects of the ACRP mutation on araC regulation were studied in an in vitro transcription system (27) . Previous work had identified transcripts originating from the araC promoter (6, 31) . Plasmids pAP-C (ara+) and pCGM3 (ACRP) were digested with BstEII and used as templates in run-off transcription experiments. The 110-nucleotide Rep RNA is not regulated by the cAMP-CRP complex (32) , and it was not regulated by araC protein and thus served as an internal control in these experiments. Synthesis of the araC transcript from the wild-type promoter was stimulated 1.6-fold by the addition of cAMP and CRP; the addition of araC protein (repressor form) reduced by 60% the amount of araC transcription, even in the presence of the cAMP-CRP complex (data not shown). When the ACRP-containing plasmid was used as template, cAMP-CRP-mediated stimulation of araC transcription was 1.2-fold and the presence of araC protein (repressor form) reduced araC transcription by 75% (data not shown). Thus, the conclusions from both in vivo and in vitro experiments on the effect of the CRP mutation on araC regulation are similar.
DNase I Protection Experiments. The effect of the ACRP mutation on the binding of the cAMP-CRP complex to the ara regulatory region was studied using the DNase I protection technique (13) . The binding of CRP to the wild-type ara regulatory region required cAMP [ Fig. 2A , compare lane 1 (no protein), lane 2 (CRP but no cAMP), and lane 3 (CRP and cAMP)]. Under these same conditions, CRP did not bind to the identical restriction fragment containing the ACRP mutation ( Fig. 2A, compare lanes 4-6) .
Protection studies were then carried out under conditions that allow binding to sites with lowered affinity for the cAMP-CRP complex. When the concentration of CRP was increased 10-fold, protection was greater at the cAMP-CRP binding site within the wild-type ara regulatory region ( Strains were transformed with pLJS1 and the resulting transformants were grown in M9 salts (15) supplemented with 0.2% glycerol, L-proline at 40 pg/ml, L-leucine at 40 ,g/ml, thiamine HCl at 1 pg/ml, and tetracycline at 5 ,ug/ml. l3-Galactosidase was assayed as described in Table 3 2B, compare lanes 1 and 2). A 10-fold increase in the concentration of CRP did not result in an observable difference in protection of the cAMP-CRP binding site when the ara regulatory region contained the ACRP mutation (Fig. 2B, compare lanes 6 and 7) . A 10-fold increase in CRP and the addition of 20% glycerol (which stimulates cAMP-CRP binding) in the binding reaction mixture resulted in complete protection of the cAMP-CRP binding site in the wild-type ara regulatoiy region (Fig. 2B, lane 3) and slight protection in the ACRP-containing ara regulatory region (Fig. 2B, lane,8) . A second cAMP-CRP binding site centered at position -130 to -140 and with a lowered affinity for CRP was observed in previous protection studies of the ara regulatory region (4, 9). Although we did not observe protection in this region of the DNA, we did observe a hypersensitive cleavage site at position -126 in both the wild-type and. ACRP-containing ara regulatory regions when the concentration of the CRP was increased 10-fold in the binding reaction mixture (Fig.  2B, lanes 2, 3, 7, and 8) .
When RNA polymerase was added with cAMP and CRP to the binding reaction mixture, protection was observed along the entire restriction fragment for both the wild-type and the ACRP-containing ara regulatory regions (Fig. 2B,   lanes 5 and 10) . The addition of RNA polymerase has been shown to reduce the amount of CRP required for binding in a DNase I protection assay (32 (Fig. 2B, lanes 4 and 9) . DISCUSSION
The ACRP mutation resulted in an araC promoter that was insensitive to changes in intracellular cAMP in vivo. The same mutation reduced araC transcription in vitro in the presence of cAMP and the CRP and reduced the affinity of the cAMP-CRP complex for the ara regulatory region in DNase I protection studies. These results clearly show that ACRP is a mutation in the araC promoter.
A reduction in promoter strength usually results in a reduction in the synthesis of the gene product. In the case of araC, however, autoregulation of the promoter by its own product counteracts the effect of reduced promoter strength. A strain that contained the ACRP mutation cis to a functional araC gene was able to repress /-galactosidase activity from a low-copy-number plasmid-encoded araC-lacZ fusion nearly as well as the wild-type strain. We tested the effects of the araC protein on the in vitro transcription from either a wildtype or a ACRP-containing araC promoter. We found that the araC protein greatly reduced promoter strength regardless of the presence of the ACRP mutation. These results show that autoregulation dominates cAMP-CRP-mediated regulation in the araC, promoter.
If ther'e is no change in araC expression associated with the ACRP mutation, then what is the role of the cAMP-CRP binding site for the araC promoter?' One possibility is that the cAMP-CRP site functions in the positive regulation of araC immediately after induction of the ara system by Larabinose. Ogden et al. (9) observed that, shortly after the addition of L-arabinose to an exponentially growing culture, transcription from the araC promoter increased as assayed by ,B-galactosidase activity in an araC-lacZ fusion strain with a functional araC gene supplied in trans by an F' episome. The increase in araC transcription was sensitive to glucose repression but the repression was reversed by the addition of 5 mM cAMP. This result suggests that autoregulation of the araC gene is either greatly reduced or nonexistent immediately after the addition of L-arabinose to a bacterial culture. Perhaps only at this time does cAMP-CRP-mediated regulation have a major effect on the rate of araC synthesis. Synthesis of araC protein occurs at an accelerated rate until its concentration reaches a level high enough that autoregulation again becomes dominant.
Previous models of ara regulation have predicted that both the AACT and ACRP mutations should decrease expression of the araBAD operon (4, 9, 10) . Physiological studies (reviewed in refs. 1 and 2) and in vitro studies (33) had shown that expression of the araBAD operon required araC protein and the cAMP-CRP complex. After DNase I protection studies showed an araC activator binding site adjacent to a cAMP-CRP binding site in the ara regulatory region, it was proposed that activation of the araBAD operon required the colinear binding of the cAMP-CRP complex, araC activator protein, and RNA polymerase (4, 9) . While the AACT mutation resulted in a loss of araBAD expression, the ACRP mutation did not affect expression or catabolite repression of (Table 2 ). The present result contrasts with an earlier result in which a negative effect of the ACRP mutation on araBA mRNA induction was seen (12) . These earlier results were probably different because the effect of the mutation was assayed from a multicopy plasmid, araC was present in a single copy on the chromosome, and induction times were short (10 min). The absence of an effect of the ACRP mutation on araBAD expression suggests that there is probably another region responsible for catabolite repression of araBAD. The nucleotide sequences of different cAMP-CRP binding sites show a great deal of homology although their locations with respect to the transcriptional initiation sites are quite variable (32, 34) . This observation has caused some confusion regarding the mechanism of transcriptional activation by the cAMP-CRP complex. It is currently not 'known whether activation requires a protein-protein interaction between the CRP and RNA polymerase or cAMP-CRP acts at a distance by changing the structure of the DNA near its binding site. One possible example for transcriptional activation at a distance was the araBAD operon because it was postulated that cAMP-CRP binding for the araBAD operon was centered >90 bp from the transcriptional start site (4, 9). Our results indicate that this site is not used by araBAD but instead is used by the adjacent araC gene. With respect to the araC transcriptional initiation site, cAMP-CRP binding is centered 54 bp upstream, a distance that is intermediate to those found in the lacZ and gal P1 promoters (32) .
The DNase I protection technique is an elegant method that allows the identification of protein binding sites in a defined region of DNA (13) . However, DNase I protection data alone should not form the basis of models for gene regulation. Rigorous proof of models for gene regulation also requires that the functionality of the proposed protein binding site be tested both in vivo and in vitro with promoter mutations as controls. This paper describes the identification of the cAMP-CRP regulatory region for the araC promoter by using an oligonucleotide-directed mutation. Contrary to earlier models proposed for araBAD expression, we believe that the site for cAMP-CRP-mediated regulation of the ara-BAD operon remains to be identified.
